Our supported
start-ups

Key figures

0
M€
invested
0
invested
companies
0
sectors in health

Discover our portfolio companies

Hephaistos Pharma
, 2023
- Paris

Hephaistos-Pharma is developing a new generation of immunostimulant to treat metastatic and hardly accessible tumors

Kimialys
, 2023
- Paris

Kimialys offers an innovative, patented chemical coating that improves the reliability of diagnostic tests.

Odimma Therapeutics
, 2023
- Strasburg

Odimma develops personalized immunotherapy using AI and synthetic DNA technology.

Abcely
, 2023
- Nantes

Abcely develops innovative medical and pharmaceutical technologies for the treatment of mucosal cancers.

Alga Therapeutics
, 2023
- Rouen

Alga Therpeutics produces cancer-fighting antibodies from micro-algae.

Bliss TX
, 2023
- Laval

A new generation of digital solutions for pain management throughout the patient journey.

Wheeleo
, 2022
- Belgium

Wheeleo is developing an innovative walking aid solution for greater independence and reduced risk of falls.

Eppur
, 2022
- Lille
Eppur is a mobility brand serving people with disabilities. With Dreeft, Eppur reinvents wheelchair braking.
Genexpath
, 2022
- Rouen

Genexpath produces and markets cancer characterization kits combined with results analysis software.

Healshape
, 2022
- Nantes

Healshape is developing a personalized, natural, regenerative and resorbable bioprosthesis for women who have undergone a mastectomy following breast cancer.

Plantibodies
, 2022
- Paris
Plantibodies develops and produces monoclonal antibodies from plants in large quantities, at lower cost and with greater safety.
Ensweet
, 2022
- Loos

Tele-rehabilitation solutions for patients with long-term conditions.

Open Stent Solutions
, 2021
- Dury

Open Stent Solution est à l’origine de la première valve mitrale stentée en forme de ruban pour un remplacement transcathéter.

Apmonia Therapeutics
, 2021
- Reims

Apmonia Therapeutics is developing a pipeline of next-generation peptide therapies targeting the tumor microenvironment to improve the lives of cancer patients.

Vaxxel
, 2021
- Lyon

Development of the first intranasal vaccine against bronchiolitis and viral pneumonia caused by human metapneumovirus and RSV.

Why did they choose Angels Santé?

"We believe that when it comes to seed financing in the healthcare sector, an innovative start-up can effectively benefit from the support of such a specialized investor, as they understand the specificity of our business model much better than generalist business angels or family office and they are more flexible than life science VCs."

Vincent Mutuel

Gaoma

"Angels Santé, in addition to other investors, has given Abcely credibility for its project in the eyes of other, more generalist co-investors, less able to appreciate the real challenges that can be encountered by a biotech company in the healthcare field, more specifically in oncology."

Jean-Marc Herbert

Abcely

"Angel Santé gives you access to a network of professional investors in the healthcare sector who are keen to get involved in your company's development. Beyond financing, you gain access to invaluable skills in a sector of expertise."

Axelle Ayad
Mapatho


our Startup Club

Angels Santé offers a "Start-up Club " dedicated to entrepreneurs supported by Angels Santé.

What the Angels Santé club has to offer:

  • exchange ideas and experiences in an exclusive setting with other health entrepreneurs,
  • you maintain and perpetuate links and create synergies between peers,
  • you are supported by our Angels Santé community, a real source of support for all our healthcare entrepreneurs.

A hands-on, interactive approach:

The club offers quarterly physical meetings, co-hosted by entrepreneurs themselves. You benefit from their feedback on a specific theme. 

Sessions are co-hosted by other speakers (associate corporate members, ecosystem players, etc.) sharing their expertise.